bc6b00643_si_001.pdf (1.74 MB)
Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy
journal contributionposted on 2016-11-21, 00:00 authored by Leilei Shi, Yi Hu, Ang Lin, Chuan Ma, Chuan Zhang, Yue Su, Linzhu Zhou, Yumei Niu, Xinyuan Zhu
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide, especially in developed countries. Although patients’ overall survival has been improved by either conventional chemotherapy or newly developed anti-angiogenesis treatment based on its highly vascularized feature, the relatively low therapeutic efficacy and severe side effects remain big problems in clinical practice. In this study, we describe an easy method to construct a novel matrix metalloproteinase-2 (MMP-2) responsive nanocarrier, which can load hydrophobic agents (camptothecin and sorafenib) with high efficiency to exert synergistic efficacy for CRC treatment. The drug-containing nanoparticles can particularly respond to the MMP-2 and realize the controlled release of payloads at the tumor site. Moreover, both in vitro and in vivo studies have demonstrated that this responsive nanoparticle exhibits much higher therapeutic efficacy than that of single antitumor agents or combined drugs coadministrated in traditional ways.
Colorectal CancerChemotherapy Colorectal canceranti-angiogenesis treatmentvivo studiesnovel matrix metalloproteinase -2antitumor agentsnanoparticle exhibitsdrugs coadministratedSynergistic TreatmentefficacyMMP -2tumor siteCRC treatmentdrug-containing nanoparticlesmatrix Metalloproteinase Responsive Nanoparticlesvascularized featureSimultaneous Anti-Angiogenesisside effects